Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pharma R&D ROI hits highest level since 2014

The pandemic continues to have a silver lining for the pharma and biotech industries.

By Brian Buntz | January 13, 2022

laboratory

Photo by Polina Tankilevitch from Pexels

The pharmaceutical industry appears to have addressed a decade-long decline in R&D productivity, according to a recent analysis from Deloitte.

In 2021, the projected R&D return on investment (ROI) rose 7%. For comparison, the ROI level in 2010 was 2.7%.

Forecast peak sales per asset hit $521 million, up more than 23% over the $422 million in peak sales in 2020.

In addition, average cycle times dipped year-on-year for the first time since 2016, falling to 6.9 years.

The development of COVID-19 therapies played a role in the gains. Phase 3 studies for such therapies were an average of 3.7 times faster than other types of Phase 3 studies.

The pandemic has led pharmaceutical companies to ramp up collaborative data sharing and data science programs, streamline protocol design and embrace other innovative strategies.

ROI in late-stage pipeline

Image courtesy of Deloitte report “Nurturing growth: Measuring the return from pharmaceutical innovation 2021”

For instance, before the pandemic, the topics of real-world data and real-world evidence were buzzwords, but their use remained limited.

“Everybody had expected that retrospective clinically derived data would start to weigh more into the decision making at the FDA, but not much took place through 2018 and 2019,” said Jeff Elton, CEO of ConcertAI. “And then we had this thing called COVID, and the amount of data — and the availability and accessibility of data — increased substantially.”

The use of real-world data also has played a role in accelerating the availability of COVID-19 vaccines, Elton said. “One of the reasons we feel more confident about accelerating, say, a vaccine authorization or moving down to even early school kids is the amount of data that we can now collect,” he said.

The level of real-world data related to the effectiveness and adverse events of COVID-19 vaccines is “actually pretty astonishing,” Elton added.

Biopharma investment also surged in 2021, according to a report from SVB. The SVB data showed that biopharma investment in 2021 hit $36.3 billion, a record level. In 2019, for instance, that sector attracted $15.9 billion in VC dollars and $25.6 billion in 2020.

The Deloitte research also found the cost to bring an asset to market has declined over the past three years. Last year, that cost was $2.0 billion. In 2019, the figure was $2.4 billion.

As the pandemic enters a new phase in 2022, time will tell if the pharmaceutical industry’s innovation momentum will continue.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development
Tagged With: biopharma, covid-19, Deloitte, pharma R&D, R&D, real-world evidence, research and development, ROI, SVB
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE